TUCSON, Ariz.--(BUSINESS WIRE)--Jun 29, 2020--
NuvOx Pharma, a Tucson-based biotechnology company developing NanO 2 ™ emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO 2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF). Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome (ARDS). ARDS, which is associated with lung inflammation leading to low blood oxygenation, is the major cause of death in COVID-19 patients. Evan Unger, MD, President and CEO of NuvOx Pharma, said, “We had data in several animal models showing that NanO 2 restored oxygen levels in conditions of low oxygen caused by ARDS or acute lung injury. We already have data in humans from when NanO 2 was tested in subjects with brain cancer and stroke showing safety and evidence of efficacy in both indications. Because of this, we designed a clinical trial to study NanO 2 in COVID-19 patients.”
Diego Martin, MD, PhD, Chairman of Radiology at McGill University, Montreal, Canada, Principal Investigator of the Canadian efforts on the trial, said, “We are excited to collaborate with NuvOx Pharma on this project. I have been collaborating with Dr. Unger to study models of myocardial infarction where we have published evidence that shows NanO 2 can act as a cardioprotectant. In addition to ARDS, COVID-19 patients suffer multi-organ damage to the heart, brain, kidneys and other organs. In fact, a large percentage of patients who succumb to COVID-19 also have underlying cardiac disease or cardiovascular risk factors. NanO 2 appears to be reversing ischemia-mediated pathways of inflammation and tissue injury in lung, heart and other tissues, which may make it particularly well-suited as a treatment in COVID-19 subjects.”
Jarrod Mosier, MD, Associate Professor with Tenure Emergency & Internal Medicine and Associate Program Director of the Critical Care Fellowship at Banner University Medical Center, Tucson, AZ, is a Principal Investigator of the US sites in the clinical trial. Dr. Mosier said, “NanO 2 will be administered as a sustained IV infusion in the clinical trial. The first phase of the trial is a dose escalation design to determine the best dose, after which additional subjects will be enrolled at that dose as a dose expansion phase. The trial will determine if NanO 2 improves clinical outcomes in COVID-19 subjects with acute hypoxic respiratory failure. NanO 2 has the potential to transform the care of COVID-19 patients who present with low oxygen saturation.”
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200629005892/en/
CONTACT: John McGonigle
KEYWORD: UNITED STATES NORTH AMERICA CANADA ARIZONA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: NuvOx Pharma
Copyright Business Wire 2020.
PUB: 06/29/2020 09:28 PM/DISC: 06/29/2020 09:28 PM